## Shabnam Jaffer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2319549/publications.pdf

Version: 2024-02-01

840776 713466 32 456 11 21 citations h-index g-index papers 32 32 32 597 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution. Cancer Reports, 2022, 5, e1481.	1.4	2
2	Mastectomy or Margin Re-excision? A Nomogram for Close/Positive Margins After Lumpectomy for DCIS. Annals of Surgical Oncology, 2022, , 1.	1.5	0
3	ASO Visual Abstract: Mastectomy or Margin Reexcision? A Nomogram for Close/Positive Margins after Lumpectomy for DCIS. Annals of Surgical Oncology, 2022, 29, 3749.	1.5	O
4	Correlation of Ki67 working group prognostic risk categories with oncotype DX recurrence score (RS) in early breast cancer (EBC) Journal of Clinical Oncology, 2022, 40, 553-553.	1.6	0
5	Measuring Invasive Breast Carcinoma on Core Biopsy: Is it Necessary?: An Analysis of Ultrasound, Mammotome, and Magnetic Resonance Imaging—Guided Core Biopsies. Archives of Pathology and Laboratory Medicine, 2021, 145, 1432-1437.	2.5	0
6	Abstract PS6-27: Secondary invasive breast events (SIBE) among patients with oncotype DX recurrence scores (RS) 26-30 and >31: Results from a large oncotype database., 2021,,.		0
7	MRI Features of Free Liquid Silicone in the Transgender Female Breast. Journal of Breast Imaging, 2021, 3, 322-331.	1.3	3
8	Trends in use of ovarian suppression (OS) for premenopausal patients with early-stage hormone positive breast cancer and Intermediate Risk (IR) Oncotype Recurrence Scores (RS) from 2006-2020: A retrospective database analysis Journal of Clinical Oncology, 2021, 39, e12522-e12522.	1.6	0
9	Tolerance of aromatase inhibitors in post-menopausal patients with early-stage hormone receptor positive (HR+) breast cancer: A real-world retrospective analysis in a large oncotype database Journal of Clinical Oncology, 2021, 39, e12532-e12532.	1.6	0
10	Application of RSClin to guide treatment recommendations for premenopausal patients with early-stage hormone-positive breast cancer and intermediate risk oncotype recurrence scores Journal of Clinical Oncology, 2021, 39, e12511-e12511.	1.6	1
11	Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26–30 and ≥31. Oncology, 2021, 99, 699-702.	1.9	1
12	Response in breast vs axilla after neoadjuvant treatment and implications for nonoperative management of invasive breast cancer. Breast Journal, 2021, 27, 120-125.	1.0	6
13	High endogenous CCL2 expression promotes the aggressive phenotype of human inflammatory breast cancer. Nature Communications, 2021, 12, 6889.	12.8	25
14	Not All Ductal Carcinomas In Situ Are Created IDLE (Indolent Lesions of Epithelial Origin). Archives of Pathology and Laboratory Medicine, 2019, 143, 99-104.	2.5	5
15	Oncotype recurrence score (RS) and discordance in patients with secondary invasive breast events (SIBE) Journal of Clinical Oncology, 2019, 37, e12016-e12016.	1.6	0
16	Stratification of oncotype (ODX) Recurrence Score (RS) by Breast Cancer Index (BCI) and its relation to discordance Journal of Clinical Oncology, 2019, 37, e12025-e12025.	1.6	0
17	Ultrasound-guided wire localization of focal ductal dilatation in the evaluation and treatment of pathologic nipple discharge. Breast Journal, 2018, 24, 356-359.	1.0	2
18	Invasive mucinous carcinoma of the breast and response patterns after neoadjuvant chemotherapy (NAC). Histopathology, 2018, 72, 965-973.	2.9	22

#	Article	IF	CITATIONS
19	A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer Journal of Clinical Oncology, 2018, 36, TPS1103-TPS1103.	1.6	1
20	The Impact of 2013 Updated ASCO/CAP HER2 Guidelines on the Diagnosis and Management of Invasive Breast Cancer: A Single-Center Study of 1739 Cases. Clinical Breast Cancer, 2017, 17, 486-492.	2.4	5
21	Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy. JAMA Oncology, 2017, 3, 36.	7.1	57
22	Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients. International Journal of Breast Cancer, 2017, 2017, 1-6.	1.2	35
23	Cellular fibroadenoma on Core needle biopsy: management recommendations for the radiologist. Clinical Imaging, 2016, 40, 587-590.	1.5	12
24	Are cytokeratinâ€positive cells in sentinel lymph nodes of patients with invasive breast carcinomas up to 5Âmm usually insignificant?. Histopathology, 2015, 66, 283-288.	2.9	2
25	Characteristics of Breast Carcinoma Cases With False-Negative Sentinel Lymph Nodes. Clinical Breast Cancer, 2014, 14, 280-284.	2.4	13
26	Excision is indicated for intraductal papilloma of the breast diagnosed on core needle biopsy. Cancer, 2009, 115, 2837-2843.	4.1	95
27	Neurothekeoma and Plexiform Fibrohistiocytic Tumor. American Journal of Surgical Pathology, 2009, 33, 905-913.	3.7	63
28	Occult Axillary Node Metastases in Breast Cancer are Prognostically Significant. Advances in Anatomic Pathology, 2008, 15, 370-373.	4.3	2
29	Immunohistochemical detection of antiapoptotic protein X-linked inhibitor of apoptosis in mammary carcinoma. Human Pathology, 2007, 38, 864-870.	2.0	37
30	Cytologic Findings of Spindle Cell Ductal Carcinoma in Situ of the Breast. Acta Cytologica, 2005, 49, 323-326.	1.3	7
31	Beyond Hematoxylin and Eosin—The Role of Immunohistochemistry in Surgical Pathology. Cancer Investigation, 2004, 22, 445-465.	1.3	34
32	Mesenteric Paraganglioma. Archives of Pathology and Laboratory Medicine, 2002, 126, 362-364.	2.5	26